Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
50 GF Score
Price NT$73.30
GF Value NT$107.89
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Great Novel Therapeutics Biotech & Medicals is: No Data: Cannot be evaluated.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Great Novel Therapeutics Biotech & Medicals Risk Assessment Related Terms

ROCO:7427 vs VRTX, REGN, MRNA: Risk Assessment Comparison

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Risk Assessment falls into.


ROCO:7427
50GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be undervalued. The current stock price of NT$73.30 is trading 32.1% below its estimated GF Value™ of NT$107.89. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Possible Value Trap.

Key valuation signals for ROCO:7427:

  • Risk Assessment:
  • GF Value™: NT$107.89 vs. price of NT$73.30 (32.1% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
50GF Score

Get the complete analysis for ROCO:7427

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$73.30
Price
NT$107.89
GF Value